Home › Compare › FMXVF vs ABBV
FMXVF yields 6022.28% · ABBV yields 3.12%● Live data
📍 FMXVF pulled ahead of the other in Year 1
Combined, FMXVF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of FMXVF + ABBV for your $10,000?
Amilot Capital Inc., a mineral resource company, acquires, explores for, develops, and exploits mineral properties in Canada and Colombia. It primarily explores for gold deposits. The company holds interest in the ANCAL property that includes 32 mining concessions, exploitation licenses, and applications covering an area of approximately 21,382 hectares situated in the Marmato/Caramanta districts in Colombia. It also holds interests in the NORTOL property, which consists of 29 mining concessions and applications covering an area of approximately 39,546 hectares located in Tolima district in Colombia; and the Papayo property that comprises approximately 400 meters of galleries covering an area of approximately 15,000 square meters located in the Tolima district in Colombia. The company was formerly known as Tolima Gold Inc. and changed its name to Amilot Capital Inc. in January 2019. The company is based in Toronto, Canada.
Full FMXVF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.